Photocure granted patent in Europe and Russia for Visonac in the treatment of acne
Both the European Patent Office and the Patent Office in Russia have issued decisions to grant a patent on Photocure's patent application "PDT Acne". The granted patents will provide protection for the use of the 5-ALA-ester methyl aminolevulinate (MAL- the active ingredient in VisonacTM) and other 5-ALA-esters in the treatment of acne until November 2025.
"We are very pleased with these decisions giving a strong patent protection on Photocure's lead dermatology product", says Kjetil Hestdal, President and CEO of Photocure. "Patent protection of our products is key to succeed in the market".
VisonacTM is a photodynamic therapy that combines the VisonacTM cream with illumination by a red light source to treat acne. Visonac(TM) cream contains MAL. The cream is applied to the acne area to be treated and after a short incubation time, the skin is illuminated with red light. The PDT procedure kills bacteria and appears to have a beneficial effect on sebaceous glands and inflammatory cells.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Putting the Brakes on Drug-Resistant HIV - Probing Multidrug Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors
Rhenovia launches drug discovery programs in rare, orphan and neglected neurodegenerative diseases - Neurological specialist will carry out research based on its unique biosimulation platforms
Gene Silencing biotechnology developed at BGU to advance Vietnamese Aquaculture
Discontinuation of sale of ceftobiprole in Switzerland
